» Articles » PMID: 35513599

Psoriatic Arthritis from a Mechanistic Perspective

Overview
Specialty Rheumatology
Date 2022 May 5
PMID 35513599
Authors
Affiliations
Soon will be listed here.
Abstract

Psoriatic arthritis (PsA) is part of a group of closely related clinical phenotypes ('psoriatic disease') that is defined by shared molecular pathogenesis resulting in excessive, prolonged inflammation in the various tissues affected, such as the skin, the entheses or the joints. Psoriatic disease comprises a set of specific drivers that promote an aberrant immune response and the consequent development of chronic disease that necessitates therapeutic intervention. These drivers include genetic, biomechanical, metabolic and microbial factors that facilitate a robust and continuous mobilization, trafficking and homing of immune cells into the target tissues. The role of genetic variants involved in the immune response, the contribution of mechanical factors triggering an exaggerated inflammatory response (mechanoinflammation), the impact of adipose tissue and altered lipid metabolism and the influence of intestinal dysbiosis in the disease process are discussed. Furthermore, the role of key cytokines, such as IL-23, IL-17 and TNF, in orchestrating the various phases of the inflammatory disease process and as therapeutic targets in PsA is reviewed. Finally, the nature and the mechanisms of inflammatory tissue responses inherent to PsA are summarized.

Citing Articles

Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.

Zabotti A, Aydin S, David P, Di Matteo A, McGonagle D Nat Rev Rheumatol. 2025; .

PMID: 40075177 DOI: 10.1038/s41584-025-01229-6.


Low apolipoprotein A1 and high apolipoprotein B levels indicate specific lipid changes in treatment naïve early psoriatic arthritis.

Ishchenko A, Van Mechelen M, Storms L, De Vlam K, Pazmino S, Neerinckx B RMD Open. 2025; 11(1.

PMID: 39778925 PMC: 11748773. DOI: 10.1136/rmdopen-2024-005174.


Serum IL-23 levels reflect a myeloid inflammatory signature and predict the response to apremilast in patients with psoriatic arthritis.

De Santis M, Tonutti A, Isailovic N, Motta F, Rivara R, Ragusa R Front Immunol. 2024; 15:1455134.

PMID: 39697337 PMC: 11652657. DOI: 10.3389/fimmu.2024.1455134.


EDIL3 alleviates Mannan-induced psoriatic arthritis by slowing the intracellular glycolysis process in mononuclear-derived dendritic cells.

Yu J, Wang X, Zhou Y, Hu J, Gu L, Zhou H Inflammation. 2024; .

PMID: 39289212 DOI: 10.1007/s10753-024-02134-y.


Secondary Immunodeficiency and Vaccine Response in Rheumatoid and Psoriatic Arthritis on Immunosuppressive Medicines.

Ocon A, Cooper S, Ramsey A, Mustafa S Cureus. 2024; 16(8):e66366.

PMID: 39246934 PMC: 11380548. DOI: 10.7759/cureus.66366.


References
1.
Lubrano E, Scriffignano S, Perrotta F . Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?. J Rheumatol. 2019; 46(11):1428-1430. DOI: 10.3899/jrheum.190054. View

2.
Scarpa R . Psoriatic Syndrome or Psoriatic Disease?. J Rheumatol. 2020; 47(6):941. DOI: 10.3899/jrheum.200051. View

3.
Leung Y, Tillett W, Orbai A, Ogdie A, Eder L, Coates L . The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates. J Rheumatol Suppl. 2020; 96:46-49. DOI: 10.3899/jrheum.200127. View

4.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8):2665-73. DOI: 10.1002/art.21972. View

5.
Moll J, WRIGHT V . Familial occurrence of psoriatic arthritis. Ann Rheum Dis. 1973; 32(3):181-201. PMC: 1006078. DOI: 10.1136/ard.32.3.181. View